Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21901867 | 0.92 | GRM4 (0.43) | GRM4GAAGFERLRRK2TDO2 | |
| SCHEMBL21901257 | 0.81 | GRM4 (0.39) | GRM4GAAGFERTDO2IDO1 | |
| SCHEMBL29535923 | 0.81 | GRM4 (0.39) | GRM4GAAGFERTDO2IDO1 | |
| SCHEMBL21901151 | 0.81 | GRM4 (0.39) | GRM4GAAGFERTDO2IDO1 | |
| SCHEMBL21900972 | 0.79 | GRM4 (0.37) | GRM4GAAGFERLRRK2TDO2 | |
| SCHEMBL30177011 | 0.72 | MAOB (0.42) | GRM4TRPA1KDR | |
| SCHEMBL21901152 | 0.71 | GAA (0.35) | GRM4GAAGFERTDO2LMNA | |
| SCHEMBL21901186 | 0.70 | ADORA2A (0.40) | — | |
| SCHEMBL22688273 | 0.67 | LRRK2 (0.38) | LRRK2 | |
| SCHEMBL22688397 | 0.67 | LRRK2 (0.38) | GRM4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-11623924-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-11 | — | — | US | disclosed |
| CN-113164761-A | Modulators of alpha-1 antitrypsin | 弗特克斯药品有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623924-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINA3, SERPINB1 | GRM4 4671/4885GAA 142/4885GFER 2732/4885 |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | GRM4 4671/4885GAA 142/4885GFER 2732/4885 |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | GRM4 4671/4885GAA 142/4885GFER 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.